{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:07:11Z","timestamp":1790014031176,"version":"4.0.1"},"reference-count":18,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Rheumatology"],"published-print":{"date-parts":[[2021,8,12]]},"abstract":"<jats:p>Objective. To study the effect of tocilizumab initiation on the lipid profile, in correlation to a composite of any cardiovascular events. Methods. A retrospective cohort study, using data from the King Faisal Specialist Hospital &amp; Research Centre database, from January 2014 to December 2019. Patients with rheumatoid arthritis or juvenile idiopathic arthritis who were \u226518 years old, initiated either on tocilizumab or other biologic treatment (anti-TNFs or Rituximab), were included, with a follow-up interval duration at a minimum of 6\u201312 months up to 3-5 years. Any patient with established cardiovascular disease or aged &lt;18 were excluded. Results. Only one cardiovascular mortality was reported in the tocilizumab group. Fifty percent of patients reached <jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mtext>high<\/a:mtext>\n                        <a:mtext>\u2009<\/a:mtext>\n                        <a:mtext>cholesterol<\/a:mtext>\n                        <a:mtext>\u2009<\/a:mtext>\n                        <a:mtext>levels<\/a:mtext>\n                        <a:mo>\u2265<\/a:mo>\n                        <a:mn>5.2<\/a:mn>\n                        <a:mtext>\u2009<\/a:mtext>\n                        <a:mtext>mmol<\/a:mtext>\n                        <a:mo>\/<\/a:mo>\n                        <a:mtext>L<\/a:mtext>\n                     <\/a:math>\n                  <\/jats:inline-formula> and <jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mtext>LDL<\/c:mtext>\n                        <c:mo>\u2265<\/c:mo>\n                        <c:mn>3.37<\/c:mn>\n                        <c:mtext>\u2009<\/c:mtext>\n                        <c:mtext>mmol<\/c:mtext>\n                        <c:mo>\/<\/c:mo>\n                        <c:mtext>L<\/c:mtext>\n                     <\/c:math>\n                  <\/jats:inline-formula> in the tocilizumab group at 36 months in a shorter time period compared to controls (60 months), <jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>P<\/e:mi>\n                     <\/e:math>\n                  <\/jats:inline-formula>\u20090.001. There were no significant differences between groups for statin use (27% vs. 28%) However, there was a significantly higher mean dose of atorvastatin in the tocilizumab group compared to controls (20.6\u2009mg vs. 16.6\u2009mg, <jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                     <\/g:math>\n                  <\/jats:inline-formula>\u20090.03). Conclusion. There was a lack of evidence of increased cardiovascular risk in correlation to hyperlipidemia secondary to tocilizumab treatment.<\/jats:p>","DOI":"10.1155\/2021\/5535486","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T23:53:32Z","timestamp":1628898812000},"page":"1-8","source":"Crossref","is-referenced-by-count":16,"title":["Tocilizumab Effect on Lipid Profile in Correlation to Cardiovascular Events: A Retrospective Cohort Study"],"prefix":"10.1155","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-6821","authenticated-orcid":true,"given":"Toka","family":"Alsulaim","sequence":"first","affiliation":[{"name":"Rheumatology Division, Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-1980","authenticated-orcid":true,"given":"Noor","family":"Alhassan","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Almutlaq","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.2174\/157488706778250168"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100717"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L268"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.4021\/jem51w"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/975028"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.07.010"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.4137\/CMAMD.S7371"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184633"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S101289"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X18798462"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1002\/art.40084"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220178"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1002\/art.41095"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207872"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2453265"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1303-y"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1186\/ar3455"}],"container-title":["International Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijr\/2021\/5535486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijr\/2021\/5535486.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijr\/2021\/5535486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T23:53:34Z","timestamp":1628898814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/ijr\/2021\/5535486\/"}},"subtitle":[],"editor":[{"given":"Tim","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":18,"alternative-id":["5535486","5535486"],"URL":"https:\/\/doi.org\/10.1155\/2021\/5535486","relation":{},"ISSN":["1687-9279","1687-9260"],"issn-type":[{"value":"1687-9279","type":"electronic"},{"value":"1687-9260","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,12]]}}}